Patients with hidradenitis suppurativa experienced
In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve...
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-02-04, 06:41
